HONOLULU – The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.
This guideline was developed in collaboration with the American Association of Neuromuscular and Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation.
Diabetic nerve pain, or neuropathy, is caused by nerve damage. "When neuropathy strikes, it is painful and can disrupt sleep; because of this it can also lead to mood changes and lower quality of life," said lead guideline author Vera Bril, MD, FRCP, with the University of Toronto and a member of the American Academy of Neurology. "It is estimated that diabetic nerve pain affects 16 percent of the more than 25 million people living with diabetes in the United States and is often unreported and more often untreated, with an estimated two out of five cases not receiving care."
According to the guideline, strong evidence shows the seizure drug pregabalin is effective in treating diabetic nerve pain and can improve quality of life; however, doctors should determine if it is appropriate for their patients on a case-by-case basis.
In addition, the guideline found that several other treatments are probably effective and should be considered, including the seizure drugs gabapentin and valproate, antidepressants such as venlafaxine, duloxetine and amitriptyline and painkillers such as opioids and capsaicin. Transcutaneous electric nerve stimulation (TENS), a widely used pain therapy involving a portable device, was also found to be probably effective for treating diabetic nerve pain.
"We were pleased to see that so many of these pain treatments had high-quality studies that support their use," said Bril. "Still, it is important that more research be done to show how well these treatments can be tolerated over time since diabetic nerve pain is a chronic condition that affects a person's quality of life and ability to function."
The recommendations of this guideline will serve as the foundation for a new set of tools the AAN is creating for doctors to measure the quality of care they provide people with nerve pain. The measures will be released in 2012.
The guidelines will also appear in the April edition of the journal Muscle and Nerve from the American Association of Neuromuscular and Electrodiagnostic Medicine as well as the April issue of PM&R, the American Academy of Physical Medicine and Rehabilitation's scientific journal.
The American Academy of Neurology, an association of more than 22,500 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, epilepsy and Parkinson's disease. For more information about the American Academy of Neurology and its upcoming Annual Meeting, visit http://www.aan.com.
The American Association of Neuromuscular and Electrodiagnostic Medicine is a nonprofit membership association dedicated to the advancement of neuromuscular, musculoskeletal and electrodiagnostic medicine. For more information about AANEM, or to learn more about this guideline or others, visit www.aanem.org.
The American Academy of Physical Medicine and Rehabilitation is the national medical society representing more than 8,000 physicians who are specialists in the field of physiatry. Physical medicine and rehabilitation specialists routinely diagnose and treat patients with medical, musculoskeletal, neurologic and neuromuscular disorders, emphasizing function, rehabilitation and quality of life. For more information about the American Academy of Physical Medicine and Rehabilitation visit www.aapmr.org.
Editor's Note: Dr. Bril will be available for media questions during a press conference at 3:00 p.m. ET/9:00 a.m. HST, on Monday, April 11, 2011, in Room 325B of the Hawaii Convention Center in Honolulu. Please contact Rachel Seroka, rseroka@aan.com, to receive conference call information for those reporters covering the press conference off-site.
Dr. Bril is available for advance interviews as well. Please contact Rachel Seroka, rseroka@aan.com, to schedule an advance interview.
To access non-late-breaking abstracts to be presented at the 2011 AAN Annual Meeting, visit http://www.aan.com/go/am11/science. Late-breaking abstracts will not be posted online in advance of the meeting and are embargoed until the date and time of presentation at the AAN Annual Meeting in Toronto or unless otherwise noted by the Academy's Media and Public Relations Department.
VIDEO: http://www.youtube.com/AANChannel
TEXT: http://www.aan.com/press
TWEETS: http://www.twitter.com/AANPublic
Journal
Neurology